Abstract
There is growing interest in the use of observational data to estimate treatment effects in chronic diseases such as multiple sclerosis (MS). The main results derived from postmarketing evaluations, in the last 2 years, of short-and long-term disease modifying drugs (DMDs) effectiveness will be reported in this Review. Moreover, some of the methodological improvements that may be useful to enhance the quality of observational studies will also be discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
McKee M, Britton A, Black N et al (1999) Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 319:312–315
D’Agostino RB Jr, D’Agostino RB Sr (2007) Estimating treatment effects using observational data. JAMA 297:314–316
Rubin DB (2007) The design versus the analysis of observational studies for causal effects: parallels with the design of randomized studies. Stat Med 26:20–36
D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281
Trojano M, Russo P, Fuiani A et al (2006) The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN exposure in multiple sclerosis. Mult Scler 12:1–8
Trojano M, Pellegrini F, Fuiani A et al (2007) New natural history of Interferon-b-treated relapsing Multiple Sclerosis. Ann Neurol 61:300–306.
Lin DY, Psaty BM, Krommal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948–963
Brown MG, Kirby S, Skedgel C et al (2007) How effective are disease modifying drugs in delaying progression in relapsingonset MS? Neurology 69:1498–1507
Trojano M (2007) Editorial: is it time to recognize the use of observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 69:1478–1479
Butzkueven H, Chapman J, Cristiano E et al (2006) MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 12:769–774
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trojano, M., Paolicelli, D., Fuiani, A. et al. Postmarketing evidence of disease-modifying drugs in multiple sclerosis. Neurol Sci 29 (Suppl 2), 225–226 (2008). https://doi.org/10.1007/s10072-008-0944-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-008-0944-z